A Phase 3, Randomized, Double-blind Study Evaluating the Efficacy and Safety of SCT630 Compared With Adalimumab in Subjects With Moderate to Severe Plaque Psoriasis
Latest Information Update: 05 Jan 2023
Price :
$35 *
At a glance
- Drugs Adalimumab (Primary)
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Sponsors Sinocelltech
- 01 Nov 2022 Results published in the International Immunopharmacology
- 26 Jan 2021 Status changed from not yet recruiting to active, no longer recruiting.
- 30 Apr 2019 New trial record